Stocks · News reference
Collaboration with NCI's Cancer Therapy Evaluation Program (CTEP) will evaluate IMNN-001in new indications and combination regimensIMUNON retains ownership of its background intellectual property with an opportunity
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced the agenda and speaker lineup for its upcoming R&D Day highlighting IMNN-001, the
Filed: 2026-08-11 AccNo: 0001493152-26-037170 Size: 204 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Imunon (NASDAQ:IMNN) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of $(0.93) by 41.94 percent. This is a 74.88 percent increase over losses of $(2.15) per share from the same